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ABSTRACT
Objective: To explore the associations between decreased pulse oximetry values (SpO2) and clinical,
laboratory, and demographic variables in general practice patients diagnosed with asthma or
chronic obstructive pulmonary disease (COPD), including those with both COPD and asthma in
combination.
Design/setting: A cross-sectional study in seven Norwegian general practices of patients aged 40
years or over who were diagnosed by their general practitioner (GP) with asthma and/or COPD. The
patients were examined during a stable phase of their disease. Patients diagnosed with COPD
(including those with combined COPD/asthma) and those diagnosed with asthma only were
analysed separately.
Main outcome measures: Decreased SpO2 values ( 95% and 92%).
Results: Of 372 patients included (mean age 61.5 years, 62% women), 82 (22.0%) had SpO2 95%,
of which 11 had SpO2 92%. In both asthma and COPD patients, SpO2 95% was significantly
associated with reduced lung function (spirometry), a diagnosis of coronary heart disease and older
age ( 65 years). In the COPD group, haemoglobin above normal was associated with SpO2 95%.
These associations were confirmed by multivariable logistic regression, where FEV1% predicted
550 was the strongest predictor of SpO2 95% (odds ratio 6.8, 95% confidence interval 2.8–16.4).
Conclusion. Pulse oximetry represents a useful diagnostic adjunct for assessing the severity of
obstructive pulmonary disease. Decreased pulse oximetry values in stable-phase patients with
asthma and/or COPD should prompt the GP to consider revising the diagnosis and treatment and
to look for co-morbidities.
KEY POINTS
 Despite its common use in general practice, the diagnostic benefits of pulse oximetry remain to
be established.
 Decreased pulse oximetry values are associated with both reduced lung function (spirometry)
and with a diagnosis of coronary heart disease.
 Decreased pulse oximetry values may reflect suboptimal treatment and/or undiagnosed
comorbidity.
 Pulse oximetry may therefore be a useful measure in the follow-up of asthma and COPD
patients in general practice.
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Pulse oximetry is a non-invasive, simple, inexpensive,
and rapid test to estimate haemoglobin oxygen satur-
ation. Hand-held pulse oximeters have become avail-
able in general practice and have been reported to be
useful diagnostic tools for the assessment of chronic
obstructive pulmonary disease (COPD) during both
stable phase [1,2] and exacerbations [1–3], and in
particular for confirming the need for oxygen therapy
[1,4,5]. Pulse oximetry may also be helpful in assessing
the severity of asthma exacerbations [1,6]. An oxygen
saturation (SpO2) 92% indicates hypoxaemia, but
values between 93% and 95% are lower than normal
[1,7,8]. In COPD patients, SpO2 values 95% predict
hypoxia during exercise and air travel [8,9]. Pulse
oximetry is regarded as a valid screening test for
systemic hypoxia [10], but current guidelines do not
inform general practitioners (GPs) how to deal with
SpO2 values between 93% and 95%. More evidence of
the usefulness of pulse oximetry is urgently needed,
because its use is rapidly increasing in general practice
[1,11,12].
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GPs implementing pulse oximetry should be able to
explain to patients the implications of a lower-than-
normal SpO2 value. The aim of this study was to describe
conditions and patient characteristics associated with
decreased pulse oximetry values in primary care patients
with stable obstructive lung disease.
Material and methods
The study was carried out at seven Norwegian GP group
practices. The practices were not randomly selected, but
were chosen based on the availability of spirometry
results from the previous five years and the type of
electronic medical record system used. Of 43 241
patients listed at the seven practices, 18 931 were
adults aged 40 or over, among whom 1784 were
identified from the medical records as being diagnosed
by the GP with asthma and/or COPD within the previous
five years. For reasons of feasibility (e.g. extra workload
for the participating GPs), each group practice decided
the proportion of registered patients with asthma or
COPD that they would invite to participate in the study.
A total of 1111 patients were invited to participate, and
in all the practices these were randomly selected in
alphabetical order among the eligible patients.
Invitations were sent by surface mail without additional
reminders. Participation required completion of a ques-
tionnaire, a meeting during a stable phase of their
disease for a clinical examination including spirometry
(i.e. baseline assessment), plus examinations during any
exacerbations in the subsequent year. This report is
based on the baseline examinations, which took place
between March 2009 and March 2010. The participants
were instructed not to take their regular respiratory
medication on the day of the examination.
Measurements and instruments
The GPs recorded comorbidities including cardiovascular
diseases on a computerized questionnaire linked to the
patient’s medical record. On a separate questionnaire,
patients recorded their smoking habits. The patient’s
height and weight were recorded to calculate their body
mass index (BMI).
Oxygen saturation was measured with a digital hand-
held pulse oximeter, Onyx II model 0550 (Nonin Medical,
Inc., Plymouth, MN, USA). The highest value obtained
from three measurements was recorded.
The HemoCue Haemoglobin system (Quest
Diagnostics, Madison NJ, USA) was used for haemoglo-
bin measurements. The thresholds for raised values were
based on the reference values used at the University
Hospital of North Norway. The upper normal limit was
16.0 g/dL for women and 17.0 g/dL for men. C-reactive
protein (CRP) was analysed using an Afinion AS100
Analyser (Axis-Shield, Oslo, Norway), Orion Quickread
CRP (Orion Diagnostica, Espoo, Finland) or ABX Micros
CRP (Horbia ABX SAS, Montpellier, France), all of which
could display values down to 8 mg/L.
Spirometry was carried out after the pulse oximetry
test, following European Respiratory Society/American
Thoracic Society guidelines [13], using a Spirare SPS310
spirometer (Diagnostica AS, Oslo, Norway). During spir-
ometry, the patients were seated and a nose clip was not
used. Post-bronchodilator spirometry was carried out 20
min after inhalation of 0.4 mg salbutamol. The post-
bronchodilator forced expiratory volume in one second
(FEV1) and forced vital capacity (FVC) were used in the
analyses. Norwegian reference values for spirometry
were applied [14].
Statistical analyses
Two thresholds of abnormal SpO2 values were used as
outcome measures,  95% and  92%. The frequencies
of reduced SpO2 associated with each patient charac-
teristic (Table I) were analysed separately in asthma and
COPD patients. The division into these two groups
was based on the GPs’ diagnosis coded as R96 (COPD)
and R95 (asthma) according to the International
Classification for Primary Care [15]. Patients who were
given both diagnoses were allocated to the COPD
group. Continuous variables (age, BMI, FEV1, and CRP)
were categorized. BMI was categorized as underweight
(520 kg/m2), normal weight/overweight (20–30 kg/m2),
and obese ( 30 kg/m2) [16]. The FEV1% predicted was
categorized as severely reduced (550%), moderately
reduced (50–80%), and normal ( 80%), in line with the
Global Initiative for Chronic Obstructive Lung Disease
grading of COPD [5]. CRP values were dichotomized into
8 mg/mL and58 mg/L. The significance of associations
between reduced SpO2 and patient characteristics was
analysed using the chi-square test. Age, sex, and
variables significantly associated with a decreased SpO2
(p50.05) in univariable analysis were entered into a
binomial multivariable logistic regression with
SpO2 95% as the outcome variable. The multivariable
analysis was also performed without categorizing the
continuous variables. SPSS version 18.0 (IBM, Armonk,
NY, USA) was used in all analyses.
Results
Of the 1111 patients invited to participate, 380 (34.2%)
accepted and attended the baseline examination. Eight
patients were excluded from analysis, two because they
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were undergoing an acute exacerbation, two because
they did not complete post-bronchodilator spirometry,
and four because they did not undergo pulse oxim-
etry. For the 372 included patients, the mean age was
61.5 years and 62% were women. A diagnosis of COPD
only was registered in 74 patients, asthma only in 206
patients, whereas 92 patients were registered with
both diagnoses. Median SpO2 was 97%. In total, 82
patients (22.0%) had SpO2 values 95%; 11 had an
SpO2 92%; of these, 10 were COPD patients and two
were on long-term oxygen therapy.
The frequency of both SpO2 92% and SpO2 95%
increased with decreasing levels of FEV1% predicted
(Figure 1). When patients with COPD and asthma were
analysed separately, the frequency of SpO2 95%
increased significantly with increasing patient age,
decreasing FEV1% predicted, and the presence of coron-
ary heart disease (Table 1). The association of coronary
heart disease with decreasing SpO2 values (p50.001) is
illustrated in Figure 2. Haemoglobin above the threshold
value was associated with SpO2 95% only in the COPD
group (Table 1). Predictors of SpO2 92% were evaluated
only in the COPD group, for which SpO2 92% was
associated with decreasing levels of FEV1% predicted,
BMI520, and raised haemoglobin values (Table 2).
Multivariable logistic regression revealed that age,
comorbidity with coronary heart disease, decreased
FEV1% predicted, and haemoglobin above normal were
all independent predictors of SpO2 95% (Table 3). The
strongest predictor of SpO2 95% was FEV1% pre-
dicted550%, recording an odds ratio of 6.8 (Table 3).
Using FEV1% predicted as a continuous variable gave
similar results and did not improve the model, with the
Nagelkerke R2 increasing only from 0.21 to 0.22. In the
logistic regression analyses, there was no significant
interaction effect between age and the other predictors.
Multivariable analysis with SpO2 92% as outcome was
not performed because of the low number of patients
with such values (n¼ 11).
Discussion
Principal findings
SpO2 95% was strongly associated with reduced lung
function, coronary heart disease, greater age, and above-
normal haemoglobin. Among the COPD patients,
Table 1. Frequency of SpO2 values 95% in 372 patients aged 40 years or more diagnosed with asthma or COPD.
COPD Asthma
SpO2 95% SpO2 95%
Patient characteristics Patients, n n (%) p-value Patients, n n (%) p-value
All 166 51 (31.7) 206 31 (15.1)
Age (years)
 65 96 37 (38.5) 0.01 55 14 0.01
565 70 14 (20.0) 151 (25.5) 17 (11.3)
Sex
Men 67 21 (31.3) 0.9 75 13 0.5
Women 99 30 (30.3) 131 (17.3) 18 (13.7)
Smoking habits
Never 22 5 (22.7) 0.7 72 13 0.7
Previous 90 28 (31.1) 83 (18.1)
Current 54 18 (33.3) 51 11 (13.3) 7 (13.7)
Coronary heart disease
Yes 42 18 (42.9) 0.05 22 7 (31.8) 0.02
No 124 33 (26.6) 184 24 (13.1)
Other cardiovascular disease
Yes 49 18 (36.7) 0.3 28 4 (14.3) 0.9
No 117 33 (28.2) 178 27 (15.2)
FEV1% predicted
480 37 6 (16.2) 0.01 122 10 (8.2) 50.01
50–80 84 24 (28.6) 78
550 45 21 (46.7) 6 17 (21.8) 4 (66.7)
BMI (kg/m2)a
520 17 9 (52.9) 0.06 4 0 (0.0) 0.3
20–30 103 27 (6.2) 142 24
 30 34 13 (38.2) 51 (16.9) 5 (9.8)
CRP (mg/L)
 8 29 12 (41.4) 0.2 29 6 (20.7) 0.4
58 137 39 (28.5) 177 25 (14.1)
Haemoglobin above normalb
Yes 16 10 (62.5) 50.01 15 2 (13.3) 0.9
No 148 40 (27.0) 190 29 (15.3)
Notes: p-values denote the significance of differences between categories of patient characteristics assessed by chi-square test. aValue
missing for 21 patients. bHb above 16.0 g/dL in women and above 17.0 g/dL in men; Hb values missing in three patients.
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SpO2 92% was also more frequently found in patients
with BMI520.
Strengths and weaknesses
In clinical practice, asthma and COPD may sometimes be
hard to differentiate [17]. The inclusion of patients
diagnosed with either or both of these conditions may
make our results relevant for the population of patients
in primary care who have obstructive lung disease. More
than half the patients in the COPD group had also been
diagnosed with asthma within the previous five years.
COPD was most frequently the later diagnosis [17], and
this may represent the trend to a change in diagnosis
from asthma to COPD [18]. Asthma can develop into
COPD [19], but the tendency to choose an asthma
diagnosis even if COPD would be more appropriate may
partly reflect the changed reimbursement regulations
for respiratory medication introduced in Norway in 2006.
At the time that this study was performed, the costs of
inhaled corticosteroids and of inhaled corticosteroids
Table 2. Frequency of SpO2 92% by patient characteristics
in 166 patients aged 40 years or over diagnosed with COPD
by a GP.
SpO2 92%
Patient characteristics Patients, n n (%) p-value
All 166 10 (6.0)
Age (years)
 65 96 7 (7.3) 0.4
565 70 3 (4.3)
Sex
Men 67 3 (4.5) 0.5
Women 99 7 (7.1)
Smoking habits
Never 22 0 0.4
Previous 90 7 (7.8)
Current 54 3 (5.6)
Coronary heart disease
Yes 42 4 (9.5) 0.3
No 124 6 (4.8)
Other cardiovascular disease
Yes 74 5(6.8) 0.7
No 92 5(5.4)
FEV1% predicted
480 37 0 (0)
50–80 84 3 (3.6)
550 45 7 (15.6) 50.01
BMI (kg/m2)a
520 17 5 (29.4) 50.01
20–30 103 4 (3.9)
 30 34 0 (0.0)
CRP (mg/L)
 8 29 3 (10.3) 0.3
58 137 7 (5.1)
Haemoglobin above normalb
Yes 16 4 (25.0) 50.01
No 148 6 (4.1)
Notes: aValue missing for 12 patients. bValue missing for two patients.
Figure 1. Frequency of reduced SpO2 by FEV1% predicted in 372
adult patients in general practice with a diagnosis of asthma
and/or COPD.
Figure 2. Frequency of coronary heart disease by pulse oximetry
values in 372 adult patients in general practice with a diagnosis
of asthma and/or COPD.
Table 3. Predictors of SpO2 95% in 369 patients aged 40 years
or over diagnosed in general practice with asthma and/or COPD.
Patient characteristics Odds ratio (95% CI) p-value
FEV1% predicted
480 Reference 0.002
50–80 2.9 (1.5–5.8) 50.001
550 6.8 (2.8–16.4)
Coronary heart disease 2.0 (1.1–3.8) 0.03
Age 1.0 (1.0–1.1) 0.004
Sex male 0.8 (0.4–1.4) 0.43
Asthma-only diagnosis 1.1 (0.6–2.1) 0.75
Haemoglobin above normal 2.5 (1.0–6.0) 0.04
Notes: CI¼ confidence interval; SpO2¼ arterial oxygen saturation measured
by pulse oximetry; FEV1¼ forced expiratory volume in one second.
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combined with long-acting b2-agonists could generally
only be reimbursed in patients with a diagnosis of
asthma. Mixed diagnoses may also reflect consultations
with more than one doctor during the five-year period.
In this study, current smoking was not associated with
decreased pulse oximetry readings. The oxygen satur-
ation in current smokers may have been overestimated,
because the presence of carboxyhaemoglobin may
falsely increase SpO2 readings [20]. Pulse oximeters also
have other limitations [7]. Oxygen saturation may be
overestimated in patients with darkly pigmented skin and
anaemia [7]. Nail polish, dirt, and artificial nails may cause
falsely low readings [21]. Poor perfusion (cold digits) may
also result in uncertain results [7]. Analysis of arterial
blood obtained by arterial puncture remains the gold
standard for measurement of oxygen saturation [7].
The low participation rate (34%) increases the risk of
including a study sample that is not representative of
the patients in primary care with asthma or COPD. It is
likely that the most severely impaired COPD patients,
who had been followed up closely in secondary care,
were less interested in taking part in the study. The same
would apply to patients at the other end of the
spectrum, namely those who felt healthy. This is
discussed in more detail in a previous report from the
study [17]. Although the prevalence of low SpO2 values
in our population might have been affected by a
somewhat skewed selection of participants, it is not
likely that the associations between decreased SpO2
values and lung function were substantially affected.
Findings in relation to other studies
The prevalence of SpO2 95% (22%) in the participants
in our study was considerably higher than that found in
the general population in a Norwegian study of 6317
adults of similar age [22]. In that study, the overall
prevalence of SpO2 95% was 6.3%, and 15.5% among
individuals with self-reported COPD [22]. In a retrospect-
ive analysis of 81 COPD patients attending a US
university medical centre and tested for desaturation
during exercise, the prevalence of SpO2 95% was 46%
[8]. In our study, 32% of the COPD patients had an
SpO2 95% (see Table 1).
We found greater age to be an independent predictor
of SpO2 95%. This was also the case in the Norwegian
population-based study [22], and we know from previ-
ous studies that lower oxygen saturation can be found in
the healthy elderly compared with that in younger
healthy adults [23].
In a Dutch study of primary care patients, Schermer
et al. [1] showed a positive association between FEV1%
predicted550 and SpO2 in COPD patients with acute
exacerbation or worsening dyspnoea, whereas the
association observed in patients with stable COPD did
not reach significance. In the Norwegian population-
based study referred to above [22], both age 65 years
and FEV1% predicted550 were strong predictors of
SpO2 95%, as in our study, but increased BMI was also
an independent predictor. This latter association was not
found in our study. A reason for this discrepancy may be
that obesity is proportionally a more common reason for
breathing problems in the general population than
among patients diagnosed with asthma or COPD. In our
study, BMI520 was strongly associated in COPD patients
with SpO2 92%. The increased occurrence of decreased
oxygen saturation in underweight COPD patients fits
with the increased COPD mortality that has been found
in patients with very low BMI [16]. In a COPD population
from primary care in the Netherlands [24], 11.7% had a
BMI518.5, similar to the 11.5% in our COPD patients
with BMI520.
In both univariable and multivariable analyses, coron-
ary heart disease was a strong predictor of SpO2 95% in
both asthma and COPD patients. An association between
coronary heart disease and decreased oxygen saturation
was also found in a study from Spain, which concluded
that pulse oximetry is useful in establishing the diagnosis
and severity of heart failure in acute myocardial infarction
[25]. Cardiovascular disease (including ischaemic heart
disease, heart failure, atrial fibrillation, and hypertension)
is probably both the most frequent and the most
important comorbidity coexisting with COPD [18, -26],
because they share similar aetiology (i.e. smoking) [27].
Cardiovascular comorbidity is probably underdiagnosed
in COPD patients [28].
Implications for primary care practice
We could not find any particular recommendations in
the guidelines for the follow-up of stable COPD and
asthma patients with SpO2 values 95% [2,5,7]. Our
study shows that patients with moderately decreased
oxygen saturation have an increased risk of severely
reduced lung function and comorbid coronary heart
disease. Some may have received suboptimal pharma-
cological treatment. Although old age may sometimes
be the only explanation, the increased risk of comorbid-
ity and of suboptimal treatment in patients with
SpO2 95% indicate that these patients should be
given special attention and followed up more closely
than patients with normal oxygen saturation. The pulse
oximeter may be a particularly helpful tool in primary
care, because it is tolerable for the patients and is easy to
use, and is thus acceptable within the time constraints of
a busy practice.
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